Crohn’s disease is a chronic, inflammatory condition that often requires long-term treatment to manage symptoms and prevent complications. And not only does it take a toll on the patient’s health, it takes a huge bite out of healthcare budgets. Managing Crohn’s disease often relies on biologic infusion therapies, which are effective but notoriously expensive. For employers and employees alike, the costs can feel staggering—causing stress, delayed care, and tough financial decisions.
Managing these costs requires more than simply shifting care to lower-cost settings. Traditional site-of-service programs still rely on the buy-and-bill model, which inflates prices through markups. Leap Health provides a transformative approach that not only reduces costs but also improves the patient experience.
The True Costs of Infusion Therapy
Entyvio, Remicade, and Humira are among the most frequently prescribed biologic therapies for Crohn’s disease due to their proven efficacy and long-standing use in managing moderate to severe cases. However, the costs of these treatments can vary significantly depending on the site of service:
|
Drug |
Outpatient Cost |
Office Cost |
Home Cost |
|
Entyvio |
$14,091 |
$9,424 |
$7,163 |
|
Remicade |
$8,033 |
$2,722 |
$3,332 |
|
Humira |
$23,764 |
$8,053 |
$9,857 |
Cutting Through the Costs
The variation is huge, but one thing is clear: you’re still paying more than you should. Leap Health eliminates unnecessary markups with its pass-through pricing model, offering unparalleled savings for employers. Here’s how Leap’s solutions compare for each drug:
- Entyvio: With Leap Health, the cost is $5,001 per dose, saving employers $2,162–$9,090 per dose, or $15,134–$63,630 annually (7 doses/year).
- Remicade: Leap delivers savings of $1,165–$6,476 per dose, translating to $4,660–$25,904 annually (4 doses/year).
- Humira: Employers save $1,653–$22,111 per dose, amounting to $19,836–$265,332 annually (12 doses/year).
By addressing the root problem, Leap Health creates real savings that go beyond what traditional site-of-service programs can achieve.
How Leap Health Transforms Infusion Therapy
Site-of-service programs may shift costs, but they don’t solve the bigger issue: an outdated system that inflates prices at every turn. Leap Health’s model delivers not just cost reductions but also a better experience for patients, who benefit from high-quality care in the comfort of their homes. Here’s how:
- Transparent Pricing: Employers pay only the true cost of specialty drugs, reducing infusion costs by up to 50%.
- Convenient Home Infusions: Employees receive treatments at home, eliminating the need for travel and facility fees while reducing disruptions to their daily lives.
- Comprehensive Care Coordination: Leap Health manages all aspects of infusion therapy, from scheduling to follow-ups, ensuring a seamless experience for patients and employers alike.
Improved adherence leads to fewer complications, better health outcomes and long-term savings—a win for both employers and employees.
The Bottom Line
Crohn’s treatments don’t have to break the bank. Leap Health is changing the game by eliminating inflated costs and delivering care where it’s most convenient for patients. By saving thousands per treatment and creating a better experience, Leap Health helps employers control costs and employees thrive.
Ready to rethink your infusion therapy strategy? Contact Leap Health today to learn more.
